Comprehensive Home Health Care

Main Office Line : 602-279-0000

Health Blog

Let's explore topics on nutrition, safety, legalities, retirement, relevant news, and more!

  • Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Tags
    Tags Displays a list of tags that have been used in the blog.

New Drug Springs Hope in Treating Alzheimer’s Disease

New research reveals promising drug for clients with early stages of Alzheimer’s Disease (AD). For decades’ scientist study protein buildup and plaque formation in the brain. Protein buildup and plaques lead to tangles, blocking the signaling of neurons and flow of nutrients into brain cells. Consequently, brain cells begin to deteriorate resulting in cognitive and behavioral changes. The PRIME study published in Nature springs hope in the treatment of AD.

 The PRIME study was conducted on 165 patients in the United States diagnosed with mild AD (Sevigny, J., et al.). Some patients received intravenous (IV) doses of aducanumab for one year, while others got a placebo. A reduction of brain plaques was noted in the group receiving IV aducanumab (Sevigny, J., et al.). The study concluded how plaque reduction helps promote cognitive health in clients with AD.  

Nature documents (Sevigny, J., et al.):

In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating—Sum of Boxes and Mini Mental State Examination scores.

The group receiving aducanumab reported few side effects including heachaches, urinary tract infections, and upper respiratory tract infections (Sevigny, J., et al.). PRIME study confirms previous hypothesis on the etiology of AD, and discovered an anti-body with positive clinical outcomes. Further studies are needed to confirm lasting brain health benefits for client with AD using aducanumab. Yet, this medical breakthrough is worth the excitement!

Reference:

Sevigny, J., Chiao, P., Bussiere, T., Weinreb, H., P., Williams, L. et all., (2016). Nature. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. V (537). doi: 10.1038/nature19323

* All information shared in this article should be discussed with your healthcare practitioner prior to incorporating any suggestions. This article is for informational purposes only, and is not intended to provide advice or direct client decisions.

in Relevant News Hits: 989
0


Yeneilyn is a Registered Nurse in the state of Florida since 2006. Her nursing practice began in the field of Cardiology at Mount Sinai Medical Hospital and expanded to care for clients in the Intensive Care Unit (ICU). She was provided the opportunity as LPN Instructor, which changed the course of her nursing career. She states, “Teaching nursing students expanded my view on positive influences nurses contribute beyond beside care. Nurses are central leaders in health education, client advocacy, and disease prevention.” Currently, Yeneilyn writes health articles and prepares Continuing Education (C.E.) courses for healthcare professionals. She continues her studies in the field of Nursing Education and evidenced-based nursing practice. In her free time she enjoys sharing time with family and friends.


For questions or topics of interest contact Nurse Yenny at: nurseyenny@gmail.com    


 


 


 

  • No comments made yet. Be the first to submit a comment

Leave your comment

Guest Monday, 20 November 2017